NCT04215211 is a clinical trial of Survival prediction for glioma patients in Glioma, sponsored by The First Affiliated Hospital of Zhengzhou University.

Who is sponsoring NCT04215211?

NCT04215211 is sponsored by The First Affiliated Hospital of Zhengzhou University.

What drugs are being tested in NCT04215211?

Interventions in NCT04215211: Survival prediction for glioma patients.

Is NCT04215211 still recruiting?

NCT04215211 is currently recruiting now. Last updated 8 February 2021.

Last reviewed 2021-02-08 · How we verify

NCT04215211

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

MR Based Survival Prediction of Glioma Patients Using Artificial Intelligence

Recruiting now Last updated 8 February 2021

What this trial tests

trial testing Survival prediction for glioma patients in Glioma in 2,500 participants. Currently enrolling.

Timeline

1 January 2017

Primary endpoint
1 January 2027

1 June 2027

Quick facts

Lead sponsor	The First Affiliated Hospital of Zhengzhou University
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	2,500
Start date	1 January 2017
Primary completion	1 January 2027
Estimated completion	1 June 2027
Sites	1 location across China

Drugs / interventions tested

Survival prediction for glioma patients

Conditions studied

Glioma — all drugs for Glioma →

Sponsor

The First Affiliated Hospital of Zhengzhou University

Who can join

Adults 1 to 90, any sex, with Glioma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This registry aims to collect clinical, molecular and radiologic data including detailed survival data, clinical parameters, molecular pathology (1p/19q codeletion, MGMT methylation, IDH and TERTp mutations, etc) and conventional/advanced/new MR sequences (T1, T1c, T2, FLAIR, ADC, DTI, PWI, etc) of patients with primary gliomas. By leveraging artificial intelligence, this registry will seek to construct and refine algorithms that able to predict patients' survivals in the frame of molecular pathology or subgroups of gliomas.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Deep learning features from diffusion tensor imaging improve glioma stratification and identify risk groups with distinct molecular pathway activities.
Yan J, Zhao Y, Chen Y, Wang W, et al · · 2021 · cited 53× · PMID 34563923 · DOI 10.1016/j.ebiom.2021.103583
Artificial Intelligence in Neurosurgery: A State-of-the-Art Review from Past to Future.
Tangsrivimol JA, Schonfeld E, Zhang M, Veeravagu A, et al · · 2023 · cited 43× · PMID 37510174 · DOI 10.3390/diagnostics13142429
Biological underpinnings of radiomic magnetic resonance imaging phenotypes for risk stratification in IDH wild-type glioblastoma.
Guan F, Wang Z, Qiu Y, Guo Y, et al · · 2023 · cited 10× · PMID 37993907 · DOI 10.1186/s12967-023-04551-3
Pre-operative imaging and post-operative appearance of standard paediatric neurosurgical approaches: a training guide for neuroradiologists.
Ganau M, Magdum SA, Calisto A. · · 2021 · cited 4× · PMID 34012863 · DOI 10.21037/tp-20-484
Radiomic profiling for insular diffuse glioma stratification with distinct biologic pathway activities.
Duan W, Wang Z, Ma Z, Zheng H, et al · · 2024 · cited 3× · PMID 38279197 · DOI 10.1111/cas.16089

Verify or expand the search:

Other recruiting trials for Glioma

Currently open trials in the same condition.

NCT07486713 — Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies · Phase 4 · recruiting
NCT07236840 — Self-administered Remote Neurological Examination Using Mobile Application in Patients With Brain Tumors · recruiting
NCT07450872 — Symptom Cluster Heterogeneity and Gut Microbiota Mechanisms in Childhood Cancer Survivors · recruiting
NCT07405372 — Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas · recruiting
NCT07338539 — BIO-SHORT: Biologically Guided Short-Course Hypofractionated RT for Poor-Prognosis GBM · Phase 2 · recruiting

Other The First Affiliated Hospital of Zhengzhou University trials

Trials by the same sponsor.

NCT07501962 — Effect of Intraluminal Administration of Menthol Solution During Colonoscopy on Colonic Spasm and Adenoma Detection Rate · NA · not yet recruiting
NCT07501975 — Effect of a Novel Colonoscopic Lavage Solution on Colonoscopy Quality · NA · not yet recruiting
NCT07454954 — The Effect of Blood Flow Restriction Training Combined With Transcranial Magnetic Stimulation on Limb Function in Hemipl · NA · not yet recruiting
NCT05114941 — Comparison of the Efficacy and Safety of Immunoadsorption and Intravenous Immunoglobulin for Guillain-Barre Syndrome · NA · not yet recruiting
NCT07314619 — Prospective, Multicenter, Single-Arm, Phase Ⅱ Clinical Study on the Efficacy and Safety of Sacituzumab Tirumotecan Combi · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04215211 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Zhengzhou University
Last refreshed: 8 February 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04215211.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing